



BE FISH+

Advanced Risk Stratification for Barrett's Esophagus

BE FISH+ is a comprehensive diagnostic panel designed to identify patients with Barrett's esophagus who are at increased risk of progression to esophageal adenocarcinoma.

By combining Cytology, IHC, and Fluorescence In Situ Hybridization (FISH) technologies, this test delivers a more complete view of dysplastic and molecular changes, which supports earlier detection and more confident clinical decision-making.

Earlier Risk Stratification Matters

Combining morphologic and molecular analysis supports more informed surveillance decisions.

Clinical Applications

- Compatible with blocks and brushing specimens
- 3–5 day turnaround time
- Available as a comprehensive panel or individual markers
- Identify patients requiring intervention vs surveillance

Why EmeritusDX?

- Advanced molecular and pathology expertise for complex cases
- Clinically actionable reporting to support confident decision-making
- Rapid turnaround times
- CAP-accredited
- CLIA-certified

Biomarker Panel Highlights

Cellular & Morphologic Analysis

- Cytology
- Feulgen

Protein Expression (IHC)

- p53
- Ki-67
- AMACR (P504S)

Molecular / FISH Probes

- MYC (8q24)
- p16 (CDKN2A, 9p21)
- HER2 (17q12)
- ZNF217 (20q13)

